This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Look to Exact Sciences, Not Radient Pharma, for Best Colon Cancer Screen Test

Stocks in this article: RXPC.PK EXAS

TUSTIN, Calif. ( TheStreet) -- Radient Pharmaceuticals' (RXPC) Onko-Sure does a lousy job of detecting early-stage colon cancer. How bad? Well, let's just say that a coin flip would be more accurate.

Newly released performance data reveals that the Onko-Sure blood test, when combined with an older blood test, successfully detected the presence of early (stage 1) colon cancer in 48% of positive samples tested.

"Highly promising" is how Radient described the new Onko-Sure data in a statement released Monday. Patients and doctors interested in catching colon cancer early so that it can be more easily treated and cured will surely disagree.

The most desirable time to detect cancer in the colon is before fast-growing cells become malignant. Exact Sciences (EXAS) is developing a test that detects genetic abnormalities in stool samples. In preliminary studies to date, Exact's Cologuard has been able to successfully detect pre-cancerous lesions in 59% of samples tested. The same Cologuard test has been able to detect 100% of stage 1 colon cancer and 96% for colon cancer in stages I-III combined.

Those are data that I'd rightfully call "highly promising."

By comparison, the combination of Radient's Onko-Sure plus the older blood test managed a sensitivity, or positive detection rate, of just 58% for all four stages of colon cancer. The tests also had a 40% false positive rate, which means they detected the presence of colon cancer in samples where no cancer actually existed.

The new Onko-Sure screening data were made public at last week's American Society of Clinical Oncology's Gastrointestinal Cancers Symposium. The results come from the so-called "Mayo Clinic" study, which Radient conducted after buying colon cancer samples from a subsidiary of the Mayo Clinic. Last year, Radient tried to mislead investors into believing that it was working in partnership with Mayo on the Onko-Sure test.

Radient past public statements about findings from the Onko-Sure colon-cancer screening study don't accurately describe the actual data released last week.

Radient markets Onko-Sure today as a test used by doctors to detect when colon cancer recurs in patients after treatment. The commercial opportunity for cancer recurrence tests is small and Radient has done a very poor job of selling Onko-Sure, evidenced by the company's dearth of revenue and a balance sheet which makes Greece look like a European economic giant.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs